Who
Michael Nally
Director
Company insider
Files Form 4 as: Director, PPG Industries; Chief Executive Officer, Generate Biomedicines; EVP, Chief Marketing Officer, Merck & Company.
In numbers
- Trades disclosed
- 91
- Buys
- 1
- Sells
- 0
- Bought
- $480K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 20 Apr 2000
- Last trade
- 11 Sep 2026
- Last filed
- 14 Sep 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 14 Sep 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code A | $10K98.088 at $105.50 | filing |
| 11 Sep 2026filed 14 Sep 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code A | $10K98.09 at $105.50 | filing |
| 12 Jun 2026filed 15 Jun 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code A | $6,72056.314 at $119.34 | filing |
| 12 Jun 2026filed 15 Jun 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code A | $6,72056.31 at $119.34 | filing |
| 16 Apr 2026filed 17 Apr 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code A | —1,684 at $0.00 | filing |
| 16 Apr 2026filed 17 Apr 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code A | —1,684 at $0.00 | filing |
| 15 Apr 2026filed 17 Apr 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code M | —1,849 at $0.00 | filing |
| 15 Apr 2026filed 17 Apr 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code M | $199K1,849 at $107.72 | filing |
| 15 Apr 2026filed 17 Apr 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code M | —1,849 at $0.00 | filing |
| 15 Apr 2026filed 17 Apr 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code M | $199K1,849 at $107.72 | filing |
| 12 Mar 2026filed 13 Mar 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code A | $7,33172.78 at $100.73 | filing |
| 12 Mar 2026filed 13 Mar 2026 | PPG PPG Industriesoption or derivative · Chemicals | SEC FORM 4 Code A | $7,33172.78 at $100.73 | filing |
| 4 Mar 2026filed 6 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $240K20,000 at $12.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Bought | $240K20,000 at $12.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Code C | —658,327 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,000,000 at $0.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,000,000 at $0.00 | filing |
| 2 Mar 2026filed 2 Mar 2026 | GENB Generate BiomedicinesBiotechnology | SEC FORM 4 Code C | —658,327 | filing |
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —844,595 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | GENB Generate Biomedicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —844,595 at $0.00 | filing |
News
Zealand And Generate Biomedicines Team Up To Develop AI-Designed Therapies For Metabolic DiseasesGENB · rttnews.com · 14 Oct 2026Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesGENB · manilatimes.net · 13 Oct 2026Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) & Generate Biomedicines (NASDAQ:GENB)GENB · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Michael Nally; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.